Reducing red blood cell transfusion in orthopedic and cardiac surgeries with Antifibrinolytics: A laboratory medicine best practice systematic review and meta-analysis.

James H Derzon¹, Nicole Clarke², Aaron Alford³, Irwin Gross⁴, Aryeh Shander⁵, Robert Thurer⁶

¹RTI International, Research Triangle Park, NC, United States of America. Electronic address: jderzon@rti.org.

²Pharmerit International, Bethesda, MD, United States of America; Vector Oncology, Memphis, TN, United States of America.

³National Network of Public Health Institutes, Washington, DC, United States of America. Electronic address: aalford@nnphi.org.

⁴Acumen Inc., San Diego, CA, United States of America. Electronic address: igross@accumen.com.

⁵Englewood Hospital and Medical Center, New Jersey, United States of America.

⁶Gauss Surgical, Los Altos, CA, United States of America.

PubMed DOI

Abstract

OBJECTIVES: To evaluate the effectiveness of antifibrinolytics tranexamic acid (TA), ε-aminocaproic acid (EACA), and aprotinin to decrease overuse of red blood cell transfusions in adult surgical and non-surgical patients. METHODS: This review followed the Centers for Disease Control and Prevention (CDC) Laboratory Medicine Best Practice (LMBP™) Systematic Review (A-6) method. Eligible studies we…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.